Prostatic carcinomas

Lentaron) gosetelin USP [65807-02-5] C59Hg4NigOi4 1269.43 (63) postmenopausal breast cancer prostatic carcinoma bone pain common... 

Zoladex) leuptohde ace-tate [74381-53-6] 059 -84 16Oi2 0 1269.47 (64) prostatic carcinoma hormonal side effects common hormonal side... 

Ranganathan S, Benetatos CA, Colamsso PJ et al (1998) Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. Br J Cancer 77 562-566... 

MH M28 M28.010 Glutamate carboxypeptidase II Diagnosis and assessment of prostatic carcinoma... 

The anabolic steroids are contraindicated in patients with known hypersensitivity to the dni, liver disorders, or serious cardiac disease, and in men with prostate gland disorders (eg, prostate carcinoma and prostate enlargement). The anabolic steroids are classified as Pregnancy Category X dru and should not be administered during pregnancy and lactation. Anabolic steroids are contraindicated when used to enhance physical appearance or athletic performance... 

In patients with breast carcinoma or prostatic carcinoma, the nurse observes for and evaluates signs indicating a response to therapy, for example, a relief of pain, an increase in appetite, a feeling of well-being. In prostatic carcinoma, the response to therapy may be rapid, but in breast carcinoma the response is usually slow. 

The male patient with inoperable prostatic carcinoma also may have concerns about taking a female hormone. The nurse assures the patient that the dosage is carefully regulated and that feminizing effects, if they occur, are usually minimal. 

Use synthetic nonapeptidc agonist analog of gonadorelin (LH-RH), gonad stimulating principle for treatment ol hormone sensitive prostatic carcinoma and endometriosis... 

Boffa L.C., Scarf S., Marian M.R., Dai40nte G, Allfrey V.G., Benatti U., Morris O. L. Dihydrotestosterone as a selective cellular/nuclear localization vector for anti-gene peptide nucleic acid in prostatic carcinoma cells. Cancer Res. 2000 60 2258-2262. 

The diagnostic usefulness should be established by appropriate retrospective or prospective studies to see if the test in fact improves the diagnostic accuracy. For inherited enzyme diseases, the measurement of the enzyme activity can be diagnostically specific and highly useful. For otherwise obvious diseases such as metastatic prostatic carcinoma, enzyme tests may be of little value (24). 

Measurement of serum acid phosphatase activities as an aid in the diagnosis and treatment of advanced prostatic carcinoma is based on the observation by Gutman and Gutman that the activity is elevated by skeletal metastases ( ). Many workers have... 

Schwartz, M. R. Greenberg, E. and Bodansky, 0. Comparative values of phosphatases and other serum enzymes in following patients with prostatic carcinoma. Cancer (1963), 16, 583-594. 

KLEIN R D and FISCHER s M (2002) Black tea polyphenols inhibit IGF-I-induced signaling through Akt in normal prostate epithelial cells and Dul45 prostate carcinoma cells , Carcinogenesis, 23 (1), 217-21. 

ZHOU J R, GUGGER E T, TANAKA T, GUO Y BLACKBURN G L and CLINTON S K (1999) Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesis in mice. J Nutr. 129 (9) 1628-35. 

Pastori, M. et al., Lycopene in association with alpha-tocopherol inhibits at physiological concentrations proliferation of prostate carcinoma cells, Biochem. Biophys. Res. Com., 250, 582, 1998. 

The normal prostate is composed of acinar secretory cells arranged in a radial shape and surrounded by a foundation of supporting tissue. The size, shape, or presence of acini are almost always altered in the gland that has been invaded by prostatic carcinoma. Adenocarcinoma, the major pathologic cell type, accounts for more than 95% of prostate cancer cases.15 Much rarer tumor types include small cell neuroendocrine cancers, sarcomas, and transitional cell carcinomas. 

The application of PSA measurements for clinical monitoring of prostatic carcinoma requires fine tuning of PSA assays. One important aspect of this tuning is to have well-defined standards (primary calibrators). Calibrators or primary reference materials consisting of PSA complexed with ACT have been prepared and are available to sponsors of commercial immunoassays. As a result of this, some sponsors have studied calibration stability and have shown that calibration did not change within 14 to 90 days. Primary references of 90 percent PSA-ACT and 10 percent f-PS A have been shown to minimize differences in PSA measurements between different assays [NCCLS Document—Primary Reference Preparations Used to Standardize Calibration of Immunochemical Assays for Serum Prostate... 

Gunasekera, RS, Sewgobind, K, Desai, S, Dunn, L, Black, HS, McKeehan, WL, and Patil, B, 2007. Lycopene and lutein inhibit proliferation in rat prostate carcinoma cells. Nutr Cancer 58, 171-177. 

PEG IL-2 Cetus/Chiron Corp. Slow release IL-2 Stage B-2 and C prostate carcinoma... 

Christiaens et al. (2004) measured cyproterone acetate (CPA), a drug used to treat prostate carcinoma, in human plasma. A LiChrosphere RP-4 (25 x 2 mm inner diameter, 25 /an, Merck KGaA) cartridge was coupled with an OminiSpher C18 column (100 x 2 mm inner diameter, 3 /an) and 30 jiL plasma was injected directly. The lower limit of quantitation (LOQ) was 300 pg/mL. Recovery was 100%. 

AKT kinases participate in pathways that regulate several cellular processes, including survival, proliferation, tissue invasion, and metabolism [5-7]. Hyperactivation of the three isoforms of AKT kinases is a common finding in human malignancies. Increased AKT-1 activity has been observed in about 40% of breast and ovarian cancers and >50% of prostate carcinomas. Activation of... 

Rat mammary tumors Lewis lung cancers Mouse mammary tumors Choriocarcinoma cells Anaplastic sarcomas Walker carcinoma cells Rat prostatic carcinomas Rat embryo fibroblasts Different malignant cells... 

C4. Chackal-Roy, R. M., Niemeyer, C., More, M., and Zetter, B. R., Stimulation of human prostatic carcinoma cell growth by factors present in human bone marrow. J. Clin. Invest. 84, 43-50 (1989). 

We conducted inhibition rate analysis for each compound using human breast carcinoma cell lines (MDA-MB-231, MCF-7) and a human prostate carcinoma cell line (PC-3). Cells were treated with various concentrations of compound for 48 hr and cellular proliferation was measured by FACs analysis. 

---